ArticlePDF Available

Partially responsive celiac disease resulting from small intestinal bacterial overgrowth and lactose intolerance

Authors:

Abstract and Figures

Celiac disease is a common cause of chronic diarrhea and malabsorption syndrome all over the world. Though it was considered uncommon in India in past, it is being described frequently recently. Some patients with celiac disease do not improve despite gluten free diet (GFD). A study described 15 cases of celiac disease unresponsive to GFD in whom small intestinal bacterial overgrowth (SIBO) or lactose intolerance was the cause for unresponsiveness. During a three-year period, 12 adult patients with celiac disease were seen in the Luminal Gastroenterology Clinic in a tertiary referral center in northern India. Two of these 12 patients (16.6%), who did not fully respond to GFD initially, are presented here. Unresponsiveness resulted from SIBO in one and lactose intolerance in the other. The former patient responded to antibiotics and the latter to lactose withdrawal in addition to standard GFD. In patients with celiac disease partially responsive or unresponsive to GFD, SIBO and lactose intolerance should be suspected; appropriate investigations and treatment for these may result in complete recovery.
Content may be subject to copyright.
BioMed Central
Page 1 of 6
(page number not for citation purposes)
BMC Gastroenterology
Open Access
Case report
Partially responsive celiac disease resulting from small intestinal
bacterial overgrowth and lactose intolerance
Uday C Ghoshal*
1
, Ujjala Ghoshal
2
, Asha Misra
1
and Gourdas Choudhuri
1
Address:
1
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India and
2
Department
of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
Email: Uday C Ghoshal* - ghoshal@sgpgi.ac.in; Ujjala Ghoshal - ujjala@sgpgi.ac.in; Asha Misra - ghoshal@sgpgi.ac.in;
Gourdas Choudhuri - gc@sgpgi.ac.in
* Corresponding author
Abstract
Background: Celiac disease is a common cause of chronic diarrhea and malabsorption syndrome
all over the world. Though it was considered uncommon in India in past, it is being described
frequently recently. Some patients with celiac disease do not improve despite gluten free diet
(GFD). A study described 15 cases of celiac disease unresponsive to GFD in whom small intestinal
bacterial overgrowth (SIBO) or lactose intolerance was the cause for unresponsiveness.
Case presentation: During a three-year period, 12 adult patients with celiac disease were seen
in the Luminal Gastroenterology Clinic in a tertiary referral center in northern India. Two of these
12 patients (16.6%), who did not fully respond to GFD initially, are presented here.
Unresponsiveness resulted from SIBO in one and lactose intolerance in the other. The former
patient responded to antibiotics and the latter to lactose withdrawal in addition to standard GFD.
Conclusion: In patients with celiac disease partially responsive or unresponsive to GFD, SIBO and
lactose intolerance should be suspected; appropriate investigations and treatment for these may
result in complete recovery.
Background
Celiac disease is a common cause of chronic diarrhea and
malabsorption syndrome (MAS) all over the world.
Though it was considered uncommon in India in past, it
is being described frequently recently [1,2]. Some patients
with celiac disease do not improve despite gluten free diet
(GFD). Tursi et al described 15 cases of celiac disease unre-
sponsive to GFD in whom small intestinal bacterial over-
growth (SIBO) or lactose intolerance was the cause of
unresponsiveness [3]. We describe two adult patients with
celiac disease only partially responsive to GFD; unrespon-
siveness resulted from SIBO in one and lactose intoler-
ance in the other.
Case presentation
During a 3-y period from July 2000 to July 2003, 12 adult
patients with celiac disease diagnosed using standard cri-
teria [2] were seen in the Luminal Gastroenterology Clinic
of the Department of Gastroenterology in a tertiary refer-
ral center in northern India. All except two (16.6%) of
them responded clinically to GFD. The data of the two
patients, who were initially unresponsive to standard GFD
is presented below.
Case 1
A 35-y-old female presented with chronic large volume
diarrhea for more than 3-y. She passed 20 liquid (includ-
ing nocturnal), frothy, pale, greasy, unusually offensive
Published: 22 May 2004
BMC Gastroenterology 2004, 4:10
Received: 24 December 2003
Accepted: 22 May 2004
This article is available from: http://www.biomedcentral.com/1471-230X/4/10
© 2004 Ghoshal et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all
media for any purpose, provided this notice is preserved along with the article's original URL.
BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/10
Page 2 of 6
(page number not for citation purposes)
stools. She never passed blood with these stools. She lost
11 kg weight in 3 y. She had temporary reduction in
diarrhea and gain in weight while on anti-tubercular drug
therapy given 3 mo after onset of this disease. She was
emaciated (body mass index 13.7 kg/m
2
), pale, had angu-
lar stomatitis and clubbed fingers. Investigations revealed:
Hb 98 g/L (normal 120–150), total leukocyte count 5.9 ×
10
9
/L (normal 4.0 – 11.0 × 10
9
) with normal differential
counts, serum albumin 30 g/L (normal 40–60), serum
iron 9.7 µmol/L (normal 11–29); serum bilirubin and
transaminases were within normal limits. ELISA test for
human immunodeficiency virus was negative. Sudan III
stained spot-stool specimen showed 15 fat droplets/high
power field (normal 10); urinary excretion over 5 h after
ingestion of 5 g D-xylose was 0.29 g (normal 1 g). Esoph-
agogastroduodenoscopy revealed flattened duodenal
folds and biopsy revealed subtotal villous atrophy, crypt
hyperplasia and increased intra-epithelial lymphocytes
(Marsh's stage IIIB) [4]. Jejunal aspirate culture by a
method described by us previously [5,6] revealed growth
of Klebsiella pneumoniae and Pseudomonas aeruginosa (col-
ony counts >10
5
CFU/ml). Glucose hydrogen breath test
(GHBT) by a standard method [5] revealed fasting value
of 36 ppm and highest value of 200 ppm 60 minutes after
100 g glucose. This was interpreted as a positive test for
SIBO as per standard criteria [5]. Lactulose hydrogen
Course of a patient with celiac diseaseFigure 1
Course of a patient with celiac disease. Her response to gluten free diet (GFD) was inadequate despite a good compliance.
This might have resulted from small intestinal bacterial overgrowth (SIBO) as addition of antibiotics with disappearance of
SIBO (as evidenced by a negative glucose hydrogen breath test, GHBT) resulted in resolution of symptoms. EMA: anti-endomy-
sial antibody.
GHBT -veTetracycline
added
Tetracycline Tetracycline
stopped
EMA +ve
GFD started
GHBT +ve
>10
5
bacteria
in jejunal fluid
0
10
20
Dec 7
2000
Jan 18
2001
April 12
2001
July 26
2001
Jan 17
2002
August 30
2002
March 13
2003
Stool/d BMI (Kg/m2) Hb (g/dL)
D-xylose 1.5 g/5 g/5 h
BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/10
Page 3 of 6
(page number not for citation purposes)
breath test by a standard technique [5] revealed two peaks;
the first peak was at 110 min after 15 ml lactulose (24
ppm above basal, basal value 17 ppm); this could be
related to SIBO. The time to second peak was 200 min
(which corresponds to oro-cecal transit time, OCTT) after
lactulose ingestion (21 ppm above basal). Therefore,
OCTT was prolonged (median value in healthy subjects in
India 65 min, range 40–110) [5]. The subsequent treat-
ment and course is depicted in Fig. 1. Though she
responded to treatment with tetracycline 500 mg t.i.d over
2 months, diarrhea recurred with reduction in body
weight 3 months after stopping the drug. At this time,
result of anti-endomysial antibody test using indirect
immunofluorescence assay (Binding Site, UK) was availa-
ble and was positive. She was started on GFD. Despite
good compliance to it, there was inadequate symptomatic
response (Fig. 1), even though D-xylose test result was
normal one y after presentation [urinary excretion over 5
h after ingestion of 5 g D-xylose 1.5 g (normal 1 g)]. In
view of finding SIBO at presentation and transient
response to antibiotics, tetracycline was re-started. She
improved symptomatically with gain in weight and nor-
malization of hemoglobin. GHBT repeated at this stage
failed to show persistence of SIBO.
Case 2
A 44-y-old female presented with large volume diarrhea
for 14 y. She passed 6–7 large volume, watery, explosive
stools everyday (including nocturnal). She gave history of
reduction of diarrhea on fasting and increase on taking
milk. She lost 9 kg weight in last 1 y. Antibiotic therapy
resulted in some reduction in stool frequency. Physical
examination revealed pallor and emaciation (BMI 16 kg/
m
2
). There was no clubbing, lymphadenopathy or orga-
nomegaly. Investigations revealed: Hb 97 g/L (normal
120–150), total leukocyte 7.7 × 10
3
/L (normal 4.0 – 11.0
× 10
9
) with normal differential counts, serum bilirubin
10.3 µmol/L (normal 2–18), alanine aminotransferase
and alkaline phosphatase 29 U/L (normal 0–40) and 88
U/L (normal <150), respectively. Serum total protein and
albumin were 57 and 27 (normal 60–84 and 35–55) g/L,
respectively; creatinine and fasting blood glucose were 53
µmol/L (normal 50–110) and 3.8 mmol/L (normal 3.9–
6.1). ELISA test for human immunodeficiency virus was
negative. Stool microscopic examination did not show
ova, cyst or parasite; fat in spot stool specimen stained
with Sudan III stain was 16 droplets/HPF (normal 10
droplets/HPF); urinary excretion over 5 h after ingestion
of 5 g D-xylose was 0.18 g (normal 1 g). Serum immu-
noglobulins were within normal limits. Esophagogas-
troduodenoscopy was normal and duodenal biopsy
revealed mild villous atrophy and broadening, crypt vil-
lous ratio 1:2 (normal 1: 3 to 5), lymphomononuclear
infiltrate in lamina propria and increased intra-epithelial
lymphocytes (Marsh's stage IIIA) [4]. Antiendomysial
antibody using indirect immunofluorescence assay (Bind-
ing Site, UK) was positive. Gluten free diet was started.
The subsequent course is shown in Fig. 2. Though she
responded to GFD to which she was fully compliant,
loose stool continued with a frequency of 4 to 5/d even 8
months after GFD. Anti-endomysial antibody repeated at
this stage was found negative. D-xylose test repeated at
this stage showed normal result [urinary excretion over 5
h after ingestion of 5 g D-xylose 1.1 g (normal 1 g)]. A
duodenal biopsy repeated 18 mo after GFD revealed
maintained villous architecture, mild lymphomononu-
clear infiltrate in lamina propria and mildly increased
intra-epithelial lymphocytes (Marsh's stage I). In view of
nearly normal villous morphology and function as was
evidenced by normal D-xylose test and negative anti-
endomysial antibody an osmotic cause like lactose intol-
erance was suspected. Lactose tolerance test and lactose
hydrogen breath test were done with 50 g oral lactose.
Fasting blood glucose and breath hydrogen were 4.6
mmol/L and 10 ppm, respectively; 1 h post lactose values
were 5.2 mmol/L and 36 ppm respectively. She had symp-
toms in the form of loose stools during 3-h observation
period. Based on these, a diagnosis of lactose intolerance
was made and lactose-free diet was started; diarrhea
resolved during follow-up (Fig. 2).
Discussion and conclusion
Diagnosis of celiac disease in both the patients was estab-
lished on standard criteria [2]. We have earlier shown that
half of patients with MAS resulting from various causes
including celiac disease may have SIBO [6]. In patients
with tropical sprue it resulted from small intestinal stasis
as evidenced by prolonged OCTT [5]. Similar mechanisms
may operate in patients with MAS due to other causes; the
patient with celiac disease with SIBO in this report had
prolonged OCTT. Prolonged OCTT has been reported by
other workers in patients with celiac disease, which nor-
malized after GFD [7]. Unabsorbed foods within the
intestinal lumen may also promote growth of bacteria in
small intestinal lumen. We believe that SIBO in patients
with MAS due to another cause may have following clini-
cal significances, (1) a response to antibiotics may lead to
a fallacious diagnosis of tropical sprue as response to anti-
biotics has been considered to be an important criterion
for diagnosis of this disease [8]; (2) it may be a cause for
inadequate response or refractory state despite GFD as
occurred in our first patient and as has been reported by
Tursi et al [3]. Lactose intolerance could be another cause
for such inadequate response to GFD. Lactase deficiency
causing intolerance to lactose is known to be either pri-
mary or secondary; though in our patient, whether it was
primary or secondary is a matter of conjecture, the latter is
more likely as degenerated intestinal epithelial cells in
patients with celiac disease are often found to have sparse
endoplasmic reticulum, reflecting low level of digestive
BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/10
Page 4 of 6
(page number not for citation purposes)
enzymes including lactase [9]; primary lactase deficiency
is somewhat uncommon too [10]. However, a definite
diagnosis of lactose intolerance is important as a firm
diagnosis helps the clinician as well as the patient to com-
pletely withdraw lactose containing foods, compliance to
which may not be so easy for a patient with celiac disease
already on significant dietary restriction without a definite
diagnosis, particularly if the patient is vegetarian. The sec-
ond patient continued to have diarrhea despite improve-
ment in D-xylose test and duodenal biopsy, which led us
to suspect a predominantly osmotic factor as the cause of
diarrhea. Therefore, we investigated for lactose intoler-
ance contributing to osmotic diarrhea. Normal result of
D-xylose test was helpful as it suggested normalization of
intestinal mucosa; D-xylose test has a high sensitivity to
detect abnormal mucosa causing MAS [11]. In fact, serial
tests of intestinal permeability, which are based on a prin-
ciple similar to D-xylose test, have been used successfully
to non-invasively predict normalization of intestinal
mucosa before undertaking invasive tests like endoscopic
duodenal biopsy [12].
Small intestinal bacterial overgrowth in patients with
celiac disease may lead to persistent diarrhea due to
Course of the other patient with celiac diseaseFigure 2
Course of the other patient with celiac disease. Her response to gluten free diet (GFD) was inadequate despite a good compli-
ance as she continued to pass 4–5 liquid stools/day. She was found to have lactose intolerance (LI). Inadequate response to
GFD might have been due to LI as withdrawal of lactose from diet resulted in complete resolution of symptoms. Other abbre-
viations used: Bx: biopsy; PVA: partial villous atrophy; EMA: anti-endomysial antibody; LHBT: lactose hydrogen breath test; LT:
lactose tolerance test.
D-xylose 0.2g/5 g/5 h
Duodenal Bx: PVA
0
10
20
May 15 2002 August 20 2002 Jan 1 2003 March 6 2003
Stool/d BMI (Kg/m2) Hb (g/dL)
D-xylose 1.1 g/5/g/5 h
Duodenal Bx: nearly
normal
LHBT, LTT +ve for LI
Lactose withdrawn
EMA +ve
GFD started
BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/10
Page 5 of 6
(page number not for citation purposes)
disturbances in luminal digestion and alteration of
mucosal function, albeit minor [13]. Bacteria in small
intestine in patients with SIBO causes deconjugation of
bile acids, which causes watery diarrhea due to stimula-
tion of colonic secretion and steatorrhea due to depletion
of bile acid pool [13]. Lactose intolerance results in per-
sistence of diarrhea mainly due to osmotic effect of unab-
sorbed lactose and flatulence due to production of gas
from fermentation of unabsorbed lactose.
Refractory celiac sprue is defined as an initial (primary) or
subsequent (secondary) failure of a strict GFD to restore
normal intestinal structure and function and may result
from several mechanisms [14]. It is important to keep all
these causes of refractory celiac sprue in mind and to
investigate and treat for all these factors [14]. Though
SIBO and secondary lactose intolerance are expected and
known to be common in celiac disease, until recently
[3,15], only a few reports have been published on this
issue [16,17]. Though normalization of duodenal histol-
ogy may take long time up to one to two years, clinical
response such as reduction in diarrhea and weight gain
occurs within weeks [14]. Failure of normalization of
duodenal histology has been proposed as a criterion for
diagnosis of refractory sprue [14]. Persistent symptoms
despite normalization of duodenal histology may suggest
causes other than refractory sprue such as SIBO and lac-
tose intolerance.
In conclusion, we believe that if diarrhea persists in a
patient with celiac disease despite improvement in duode-
nal biopsy and D-xylose absorption, lactose intolerance
and SIBO should be suspected; appropriate investigations
and treatment for these may result in complete recovery.
List of abbreviations
GFD: gluten free diet
SIBO: small intestinal bacterial overgrowth
MAS: malabsorption syndrome
Hb: hemoglobin
ELISA: enzyme linked immunosorbant assay
CFU: colony forming units
GHBT: glucose 'hydrogen breath test
PPM: parts per million
OCTT: orocecal transit time
BMI: body mass index
HPF: high power field
UK: United Kingdom
LI: lactose intolerance
Bx: biopsy
PVA: partial villous atrophy
EMA: endomysial antibody
LHBT: lactose hydrogen breath test
LT: lactose tolerance test
Declaration of competing interests
None declared.
Authors' contribution
Uday C Ghoshal was the clinician involved in the man-
agement of these patients, conceived the idea and drafted
the manuscript. Ujjala Ghoshal standardized and per-
formed microbiological works for the diagnosis of small
intestinal bacterial overgrowth syndrome. Asha Misra per-
formed the hydrogen breath tests. Gourdas Choudhuri
supervised the works. All the authors read and approved
the manuscript.
Acknowledgement
We thank the patients who are presented in this report for giving us writ-
ten consent for publishing their data.
References
1. Mahindra S, Yaccha SK, Srivastava A, Krishnani N, Aggarwal R,
Ghoshal UC, Prasad KK, Naik SR: Celiac disease in Asian Indian
children: Anthropometric and histological study. J Pop Health
Nutr 2001, 19:204-8.
2. Poddar U, Thapa BR, Nain CK, Prasad A, Singh K: Celiac disease in
India: Are they true cases of celiac disease? J Pediatr Gastroen-
terol Nutr 2002, 35:508-512.
3. Tursi A, Brandimarte G, Giorgetti GM: High prevalence of small
intestinal bacterial overgrowth in celiac patients with per-
sistence of gastrointestinal symptoms after gluten
withdrawal. Am J Gastroenterol 2003, 98:839-43.
4. Marsh MN: Gluten, major histocompatibility complex and
small intestine: A molecular and immunological approach to
the spectrum of gluten sensitivity (celiac sprue). Gastroenterol-
ogy 1992, 102:330-54.
5. Ghoshal UC, Ghoshal U, Ayyagari A, Ranjan P, Krishnani N, Misra A,
Aggarwal R, Naik S, Naik SR: Tropical sprue is associated with
contamination of small bowel with aerobic bacteria and
reversible prolongation of orocecal transit time. J Gastroenterol
Hepatol 2003, 18:540-7.
6. Ghoshal U, Ghoshal UC, Ranjan P, Ayyagari A: Spectrum and anti-
biotic sensitivity of bacteria contaminating upper gut in
patients with malabsorption syndrome in the tropics. BMC
Gastroenterology 2003, 3:9 [http://www.biomedcentral.com/1471-
230X/3/9].
7. Chiarioni G, Bassotti G, Germani U, Battaglia E, Brentegani MT,
Morelli A, et al.: Gluten-free diet normalizes mouth-to-cecum
transit of a caloric meal in adult patients with celiac disease.
Dig Dis Sci 1997, 42:2100-5.
Publish with BioMed Central and every
scientist can read your work free of charge
"BioMed Central will be the most significant development for
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/10
Page 6 of 6
(page number not for citation purposes)
8. Lim ML: A perspective on tropical sprue. Curr Gastroenterol Rep
2001, 3:322-7.
9. Farrell RJ, Kelly CP: Celiac sprue and refractory sprue. In: Gas-
trointestinal and Liver Disease. Pathophysiology, Diagnosis, Management
Edited by: Feldman M, Friedman LS, Sleisenger MH. Philadelphia: WB
Saunders; 2002:1817-41.
10. Heitlinger LA, Lebenthal E: Disorders of carbohydrate digestion
and absorption. Pediatr Clin North Am 1988, 35:239-55.
11. Bala L, Gowda GAN, Ghoshal UC, Misra A, Bhandari M, Khetrapal
CL:
1
H spectroscopic method for diagnosis of malabsoprtion
syndrome: A pilot study. NMR Biomedicine 2004, 17:69-75.
12. Johnston SD, Smye M, Watson RGP: Intestinal permeability test
in celiac disease. Clin Lab 2001, 47:143-50.
13. Isaacs PET, Kim YS: The contaminated small bowel syndrome.
Am J Med 1979, 67:1049-56.
14. Ryan BM, Kelleher D: Refractory celiac disease. Gastroenterology
2000, 119:243-51.
15. Abdulkarim AS, Burgart LJ, See J, Murray JA: Etiology of nonre-
sponsive celiac disease: Reults of a systemic approach. Am J
Gastroenterol 2002, 97:2016-21.
16. Fine K, Meyer R, Lee E: The prevalence and cause of chronic
diarrhea in patients with celiac sprue treated with a gluten
free diet. Gastroenterology 1997, 112:1830-8.
17. Roufail W, Ruffin J: Effect of antibiotic therapy on gluten sensi-
tive enteropathy. Am J Dig Dis 1966, 11:587-93.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/4/10/pre
pub
... Celiac disease seems to certainly correlate with intestinal microbiota composition. The connection between SIBO and celiac disease has been studied since 1970 and the prevalence of SIBO was as high as 66.66% according to published data [32][33][34][35]38]. Precursory studies implied that due to GI dysmotility, the patient's condition was further complicated by the presence of gut dysbiosis. ...
Article
Full-text available
The microbiota, as a complex of microorganisms in a particular ecosystem, is part of the wider term—microbiome, which is defined as the set of all genetic content in the microbial community. Imbalanced gut microbiota has a great impact on the homeostasis of the organism. Dysbiosis, as a disturbance in bacterial balance, might trigger or exacerbate the course of different pathologies. Small intestinal bacterial overgrowth (SIBO) is a disorder characterized by differences in quantity, quality, and location of the small intestine microbiota. SIBO underlies symptoms associated with functional gastrointestinal disorders (FGD) as well as may alter the presentation of chronic diseases such as heart failure, diabetes, etc. In recent years there has been growing interest in the influence of SIBO and its impact on the whole human body as well as individual systems. Therefore, we aimed to investigate the co-existence of SIBO with different medical conditions. The PubMed database was searched up to July 2022 and we found 580 original studies; inclusion and exclusion criteria let us identify 112 eligible articles, which are quoted in this paper. The present SIBO diagnostic methods could be divided into two groups—invasive, the gold standard—small intestine aspirate culture, and non-invasive, breath tests (BT). Over the years scientists have explored SIBO and its associations with other diseases. Its role has been confirmed not only in gastroenterology but also in cardiology, endocrinology, neurology, rheumatology, and nephrology. Antibiotic therapy could reduce SIBO occurrence resulting not only in the relief of FGD symptoms but also manifestations of comorbid diseases. Although more research is needed, the link between SIBO and other diseases is an important pathway for scientists to follow.
... Of the 14 studies retained, five were case-control studies, 15,[20][21][22][23] and the remaining nine were cohort studies. 3,4,13,14,[24][25][26][27][28] The characteristics of all the studies included in this meta-analysis including the methodology pertaining to diagnosis of SIBO and patient characteristics are outlined in Table 2 and Tables S2 and S3. ...
Article
Full-text available
Background and aims: Symptoms of small intestinal bacterial overgrowth (SIBO) and celiac disease (CeD) often overlap, and studies suggest a link between SIBO and CeD. We thus conducted a systematic review and meta-analysis to compare SIBO prevalence in CeD-patients and controls and assessed effects of antimicrobial therapy on gastrointestinal symptoms in SIBO positive CeD-patients. Methods: Electronic databases were searched until February-2022 for studies reporting SIBO prevalence in CeD. Prevalence rates, Odds Ratio (OR) and 95% confidence intervals (CI) of SIBO in CeD and controls were calculated. Results: We included 14 studies, with 742 CeD-patients and 178 controls. The pooled prevalence of SIBO in CeD was 18.3%(95%CI:11.4-28.1), with substantial heterogeneity. Including case-control studies with healthy controls, SIBO prevalence in CeD-patients was significantly increased (OR5.1, 95%CI:2.1-12.4, p=0.0001), with minimal heterogeneity. Utilizing breath tests, SIBO prevalence in CeD-patients was 20.8%(95%CI:11.9-33.7), almost two-fold higher compared to culture-based methods at 12.6%(95%CI:5.1-28.0), with substantial heterogeneity in both analyses. SIBO prevalence in CeD-patients nonresponsive to a gluten free diet (GFD) was not statistically higher as compared to those responsive to GFD (OR1.5, 95%CI:0.4-5.0, p=0.511). Antibiotic therapy of SIBO positive CeD-patients resulted in improvement in gastrointestinal symptoms in 95.6%(95%CI:78.0-99.9) and normalization of breath tests. Conclusions: This study suggests a link between SIBO and CeD. While SIBO could explain nonresponse to a GFD in CeD, SIBO prevalence is not statistically higher in CeD-patients non-responsive to GFD. The overall quality of the evidence is low, mainly due to substantial 'clinical heterogeneity' and the limited sensitivity/specificity of the available diagnostic tests.
... In a subset with NRCD, in whom celiac-specific serology is negative and the biopsies also show no active enteropathy, it is very likely that the symptoms in such patients are not gluten induced and may be caused by many co-existent diseases such as irritable bowel syndrome, food intolerance, small intestinal bacterial overgrowth [81,82], microscopic colitis or pancreatic insufficiency that cause similar gastrointestinal symptoms. They should be investigated and treated appropriately [83À86]. ...
Chapter
A gluten-free diet (GFD) is the current standard of care for all patients with celiac disease (CeD) including its classic, nonclassic, and silent forms, as well as for dermatitis herpetiformis, gluten ataxia, and nonceliac gluten sensitivity. Following a GFD involves restricting certain food items, thus care must be taken to ensure a balanced diet that provides both macronutrients and micronutrients. Further, a GFD requires major lifestyle changes for the patients and their families. Moreover, despite attempts to maintain a strict GFD, gluten exposure is common given the extensive use of gluten in the food industry. Hence, repeated and accurate counseling of patients and their families by skilled/specialized dieticians forms an essential part of the treatment. Other best practices to be considered by physicians include monitoring and correction of nutritional deficiencies related to CeD, prevention of bone loss, vaccinations for certain infections, voluntary screening of family members, and keeping a high index of suspicion for CeD-associated autoimmune disorders and extraintestinal manifestations affecting the liver, bone, etc. All patients with CeD should be assessed at regular intervals for improvement and adherence on a GFD, since almost a third of patients fail to show a satisfactory response. Monitoring and appropriate treatment of issues uniquely associated with a GFD, including a higher risk of metabolic syndrome, fatty liver, dietary deficiencies, and constipation, are also important. Interestingly, insights gleaned into the pathogenesis of CeD over the past two decades have provided options for targeted therapies that may be useful as alternatives/adjunctive to a GFD. Based on their mechanisms of action, these therapies may be classified as belonging to one of the following approaches. The first approach involves decreasing the immunogenicity of gluten, using glutenases like latiglutenase or kuma, genetic modification of wheat that is the most common source of gluten, microwave thermal treatment of hydrated wheat kernels, and gluten pretreatment prior to ingestion, with either bacterial/fungal-derived endopeptidases or microbial transglutaminase. The second approach involves intraluminal gluten-binding drugs like polymer p(HEMA-co-SS), single-chain fragment variable, and antigluten antibody AGY. The third approach antagonizes zonulin, a molecule regulating intestinal epithelial tight junctions that mediate gliadin transport. The fourth approach involves intestinal tissue transglutaminase enzyme inhibition to decrease deamidation of gliadin peptides taken-up by the mucosa, into epitopes with enhanced immunogenicity, using agents like ZED1227, si-RNA therapy, etc. The fifth approach seeks to prevent downstream immune activation after exposure to gliadin peptides, using Human Leukocyte Antigen blockers that prevent presentation of gluten-derived antigens by dendritic cells to T cells, immune-tolerizing therapies like the vaccine Nexvax2 and the nanoparticle-based Tolerogenic Immune Modifying Particles-Glia, cathepsin inhibitors, corticosteroids, elafin, etc., and anticytokine agents targeting interleukin-15/interleukin-21, CCR9–CCL25 interaction, γc receptor, etc. Overall, among the novel therapies on the anvil, glutenases, and strategies that modulate immune activation appear to be some of the promising therapies based on preliminary results.
... Causes of secondary lactose intolerance are; celiac disease, giardiasis, infectious enteritis, mucosal injury, bacterial overgrowth and drug induced enteritis. [7][8] Malnutrition occurs when there is mismatch between body's nutrient requirements and intake. That results in deficiency of energy, protein, and micronutrients that can affects growth, development, and other relevant outcomes. ...
Article
Objective: To determine the frequency of lactose intolerance in malnourished children presenting with acute watery diarrhea. Study Design: Cross Sectional study. Setting: Department of Pediatrics at The Children’s Hospital & the Institute of Child Health. Period: 20th December 2015 till 20th June 2016. Material & Methods: A total of 225 children fulfilling inclusion criteria were selected. Stool samples were tested for reducing substances after informed consent from parents. Approval from Ethical Committee was taken. Data was entered and analyzed through SPSS 2.0. Results: Out of total 225 patients with age 3 months to 2 years (mean age 13.41±5.93 months), 112 (49.8%) were males and 113 (50.2%) were females. Overall lactose intolerance was observed in 57 (25.3%) patients, out of which, 27 (24.1%) were males and 30 (26.5%) were females. Total of 129 (57.3%) had low socio-economic status out of which 35 (27.1%) had lactose intolerance. Conclusion: In these malnourished children with acute watery diarrhea, lactose intolerance is high and local guidelines are necessary for proper screening and management.
... In 2003, Tursi et al. performed LBT in 15 celiac patients with gastrointestinal symptoms despite GFD. SIBO was found in the 66.66% and symptoms improved after treatment with rifaximin [37]. Similar results were obtained by Ghoshal et al. in 12 celiac patients, two of which did not respond to GFD and were tested for jejunal aspirate culture, GBT and LBT; in this series, a patient was affected by SIBO and was treated with tetracycline with a good outcome [38]. ...
Article
Full-text available
Small intestinal bacterial overgrowth (SIBO) is a condition hallmarked by an increase in the concentration of colonic-type bacteria in the small bowel. Watery diarrhea, bloating, abdominal pain and distension are the most common clinical manifestations. Additionally, malnutrition and vitamin (B12, D, A, and E) as well as minerals (iron and calcium) deficiency may be present. SIBO may mask or worsen the history of some diseases (celiac disease, irritable bowel disease), may be more common in some extra-intestinal disorders (scleroderma, obesity), or could even represent a pathogenetic link with some diseases, in which a perturbation of intestinal microbiota may be involved. On these bases, we performed a review to explore the multiple links between SIBO and digestive and extra-intestinal diseases.
... (10,14,15,18,30), 16.9%, with a range 8.3%-21.57% using GHBT (11,12,31), and 24.6%, with a range 9.39%-50% using cultures of the jejunal fluids (13,16,17). Although the most common cause of CeD that is unresponsiveness to GFD is the inadvertent consumption of gluten, other causes have been described including SIBO (13,18). ...
Article
Full-text available
Background/aims: Little is known about the relationship between small intestinal bacterial overgrowth (SIBO) and celiac disease (CeD) in patients who are unresponsive to a gluten-free diet (GFD). This study aimed to determine the SIBO prevalence in patients with CeD who are unresponsive to a GFD. Materials and methods: We conducted a case-control study from July 2012 to September 2014. We included 32 patients with CeD who were unresponsive to a GFD and 52 healthy age- and sex-matched controls. Demographic, clinical, and laboratory data were obtained from patients' medical records. Antitissue transglutaminase antibody determined by enzyme-linked immunosorbent assay was recorded, and lactulose hydrogen breath test (LHBT) was used to detect SIBO in all participants. Microbiological analysis, including jejunal aspirates obtained using upper endoscopy, was performed for only 20 patients with CeD. Results: A total of 10 (31%) of 32 patients with CeD and 4 (7.7%) of 52 controls tested positive for LHBT, with a statistically significant difference (p=0.007). Of 20 cultures, 3 (15%) were positive with no statistically significant correlation between the cultures and LHBT (p=0.05). In a subgroup analysis of children who were 18 years old or younger, 7/24 (29.2%) patients with CeD had a positive LHBT compared with 3/32 (9.4%) controls, but this difference was not statistically significant (p=0.08). Conclusion: The prevalence of SIBO was 31% in unresponsive patients with CeD according to LHBT and 15% in the quantitative culture of the jejunal aspirate, which is comparable with the published Western literature.
... [16] LHBT ile laktoz intoleransı saptanan yetişkinlerde çölyak hastalığı sıklığını araştırdıkları bir çalışmada, hastaların %24'ünde, kontrol grubunun da %2'sinde çölyak hastalığı saptamışlardır. Yetişkinlerde yapılan iki farklı çalışmada ise, GD'ye cevap vermeyen çölyak hastalarında LHNT ile laktoz intoleransı olduğu gösterilmiştir [19,20]. Benzer olarak Leffler ve ark. ...
Article
Background: Small intestinal bacterial overgrowth (SIBO), although associated with potentially serious complications, has not been adequately studied in critically ill patients. The primary objective of this study was to assess the prevalence of SIBO in critically ill patients. Secondary outcomes included the assessment of its effect on ventilator-associated pneumonia (VAP), intensive care unit (ICU) length of stay (LOS), and all-cause in-hospital mortality rate. Methods: This prospective observational study was conducted in a mixed medical-surgical ICU. In 52 consecutive ICU patients, a noninvasive modified hydrogen breath test (HBT) with lactulose was employed for SIBO diagnosis. The HBT was conducted at predetermined time intervals (first day of admission; third, fifth, and seventh day of ICU stay). Patients with an abnormal HBT suggesting SIBO on the day of ICU admission were excluded from the study. Participants were classified as either positive or negative based on their HBT on the third, fifth, and/or seventh day. A comparative assessment of demographic data, APACHE II score, incidence of VAP, duration of ICU stay, and all-cause in-hospital mortality was conducted. Multivariate logistic regression analysis was performed to identify the predictive factors for SIBO. Results: The groups were homogeneous in terms of their baseline characteristics. The prevalence of SIBO was 36.5%. The all-cause in-hospital mortality was 34.6%. The presence of SIBO was associated with an increased incidence of VAP (P < .001) and a prolonged ICU length of stay (P < .033). All-cause in-hospital mortality was similar between the groups. Regarding the results of the multivariate logistic regression model, only age was identified as a statistically significant independent predictor of SIBO (OR 1.08, P = .018). Conclusions: The prevalence of SIBO in ICU patients appears to be increased. Both early diagnosis and effective treatment are of utmost importance, especially for critically ill patients since it appears to be associated with VAP and prolonged hospitalization.
Article
Full-text available
Individuals with celiac disease (CeD) often experience gastrointestinal symptoms despite adherence to a gluten-free diet (GFD). While we recently showed that a diet low in fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs) successfully provided symptom relief in GFD-treated CeD patients, there have been concerns that the low FODMAP diet (LFD) could adversely affect the gut microbiota. Our main objective was therefore to investigate whether the LFD affects the faecal microbiota and related variables of gut health. In a randomized controlled trial GFD-treated CeD adults, having persistent gastrointestinal symptoms, were randomized to either consume a combined LFD and GFD (n = 39) for four weeks or continue with GFD (controls, n = 36). Compared to the control group, the LFD group displayed greater changes in the overall faecal microbiota profile (16S rRNA gene sequencing) from baseline to follow-up (within-subject β-diversity, P < 0.001), characterized by lower and higher follow-up abundances (%) of genus Anaerostipes (Pgroup < 0.001) and class Erysipelotrichia (Pgroup = 0.02), respectively. Compared to the control group, the LFD led to lower follow-up concentrations of faecal propionic and valeric acid (GC-FID) in participants with high concentrations at baseline (Pinteraction ≤ 0.009). No differences were found in faecal bacterial α-diversity (Pgroup ≥ 0.20) or in faecal neutrophil gelatinase-associated lipocalin (ELISA), a biomarker of gut integrity and inflammation (Pgroup = 0.74), between the groups at follow-up. The modest effects of the LFD on the gut microbiota and related variables in the CeD patients of the present study are encouraging given the beneficial effects of the LFD strategy to treat functional GI symptoms. (Registered at clinicaltrials.gov as NCT03678935).
Article
The concept of small intestinal bacterial overgrowth (SIBO) arose in the context of maldigestion and malabsorption among patients with obvious risk factors that permitted the small bowel to be colonized by potentially injurious colonic microbiota. Such colonization resulted in clinical signs, symptoms and laboratory abnormalities that were explicable within a coherent pathophysiological framework. Coincident with advances in medical science, diagnostic testing evolved from small bowel culture to breath tests and on to next generation, culture-independent microbial analytics. The advent and ready availability of breath tests generated a dramatic expansion in both the rate of diagnosis of SIBO and the range of associated gastrointestinal and non-gastrointestinal clinical scenarios. However, issues with the specificity of these same breath tests have clouded their interpretation and aroused some skepticism regarding the role of SIBO in this expanded clinical repertoire. Furthermore, the pathophysiological plausibility that underpins SIBO as a cause of maldigestion/malabsorption is lacking in regard to its purported role in irritable bowel syndrome, for example. One hopes that the application of an ever-expanding armamentarium of modern molecular microbiology to the human small intestinal microbiome in both health and disease will ultimately resolve this impasse and provide an objective basis for the diagnosis of SIBO.
Article
Full-text available
This article examines associations between gluten, polymorphisms of the major histocompatibility complex, and mucosal pathology representative of the spectrum of gluten sensitivity. Sequences of wheat, rye, and barley prolamins contain recurring tetrapeptide motifs that are predicted to have beta-reverse-turn secondary structure and that, with in vitro assays, appear active. Structural polymorphisms of major histocompatibility complex subloci identify codon switches within the second exon that control the third hypervariable region in the outer domain of the beta chain. Observations of the intestinal response to gluten reveal five interrelated lesions (preinfiltrative, infiltrative, hyperplastic, destructive, and hypoplastic) that are interpretable as cell-mediated immunologic responses. These responses originate in the lamina propria, where a series of antigen-specific inflammatory processes has now been identified. There is no evidence that celiac sprue is a disease of jejunal enterocytes. Furthermore, the role of intraepithelial space lymphocytes in pathogenesis, if relevant, needs further experimental dissection. Also awaiting further definition are polymorphisms of the celiac lymphocyte antigen receptor and their relationship to gliadin oligopeptide(s) and predisposing genes. The nature and basis of nonresponsive celiac sprue require more thoughtful initiatives to elucidate the immunologic mechanism(s) of unresponsiveness and evaluate possible means of reversal. Finally, a more sensible definition of gluten sensitivity (unhampered by qualitative morphological imagery) is ultimately called for in order to accommodate the biomolecular advances addressed in this review.
Article
Celiac disease is a gluten-sensitive enteropathy with a broad spectrum of clinical manifestation, and most celiac patients respond to a gluten-free diet (GFD). However, in some rare cases celiacs continue to experience GI symptoms after GFD, despite optimal adherence to diet. The aim of our study was to evaluate the causes of persistence of GI symptoms in a series of consecutive celiac patients fully compliant to GFD.Methods We studied 15 celiac patients (five men, 10 women, mean age 36.5 yr, range 24–59 yr) who continued to experience GI symptoms after at least 6–8 months of GFD (even if of less severity). Antigliadin antibody (AGA) test, antiendomysial antibody (EMA) test, and sorbitol H2-breath test (H2-BT), as well as esophagogastroduodenoscopy (EGD) with histological evaluation, were performed before starting GFD. Bioptic samples were obtained from the second duodenal portion during EGD, and histopathology was expressed according to the Marsh classification. To investigate the causes of persistence of GI symptoms in these patients, we performed AGA and EMA tests, stool examination, EGD with histological examination of small bowel mucosa, and sorbitol-, lactose-, and lactulose H2-breath tests.ResultsHistology improved in all patients after 6–8 months of GFD; therefore, refractory celiac disease could be excluded. One patient with Marsh II lesions was fully compliant to his diet but had mistakenly taken an antibiotic containing gluten. Two patients showed lactose malabsorption, one patient showed Giardia lamblia and one patient Ascaris lumbricoides infestation, and 10 patients showed small intestinal bacterial overgrowth (SIBO) by lactulose H2-BT. We prescribed a diet without milk or fresh milk–derived foods to the patient with lactose malabsorption; we treated the patients with parasite infestation with mebendazole 500 mg/day for 3 days for 2 consecutive wk; and we treated the patients with SIBO with rifaximin 800 mg/day for 1 wk. The patients were re-evaluated 1 month after the end of drug treatment (or after starting lactose-free diet); at this visit all patients were symptom-free.Conclusions This study showed that SIBO affects most celiacs with persistence of GI symptoms after gluten withdrawal.
Article
Background: In tropical sprue (TS), response to antibiotics may suggest a role for bacterial contamination of the small bowel, which is known in diseases with prolonged orocecal transit time (OCTT). Methods: We studied 13 patients with TS (diagnosed by standard criteria) for frequency, nature and degree of bacterial contamination of the small bowel by quantitative culture of jejunal aspirate, glucose hydrogen breath test (GHBT), and OCTT by lactulose hydrogen breath test before and after treatment. Twelve patients with constipation-predominant irritable bowel syndrome (IBS) and 12 healthy subjects served as controls. Results: Ten of 13 patients with TS had bacterial contamination compared with 3/12 with IBS (all aerobic, P < 0.05). Median colony count in TS (36 000 CFU/mL, 400 to > 100 000) was higher than IBS (700 CFU/mL, 100–1000, P < 0.05). Gram-negative aerobic bacilli were commonly isolated in TS but not in IBS. Median OCTT was longer in TS (180 m, 40 − 240) than IBS (110 m, 70 − 150, P = 0.008) and healthy subjects (65 m, 40 − 110, P = 0.0007, Wilcoxon rank sum test). Orocecal transit time in TS correlated with fecal fat (Spearman's rank correlation coefficient 0.69, P < 0.05). Orocecal transit time and fecal fat, repeated in 8/13 patients, decreased with treatment for TS (195 m, 130–240 vs 125 m, 90–200, P = 0.02; 8 g/24 h, 6.8–19.6 vs 7 g/24 h, 4.2–9, P = 0.04, respectively). Conclusion: Aerobic bacterial contamination of the small bowel is common in patients with TS. Prolonged OCTT in TS correlated with fecal fat and normalized in a subset of patients after treatment. © 2003 Blackwell Publishing Asia Pty Ltd
Article
In 2 cases of gluten-sensitive enteropathy, clinical recovery, partial in one and complete in the other, followed the administration of a gluten-free diet. When challenged with gluten both patients had a pronounced relapse. After the prolonged administration of tetracycline both patients have resumed a normal diet and show no effect when challenged with gluten. If these results can be confirmed in other patients, there must be a factor other than gluten in the so-called gluten-sensitive enteropathy.
Article
Contamination of the small bowel with an abnormal microflora causes a variety of disturbances of intraluminal digestion and of mucosal function resulting in malabsorption of fat, protein, carbohydrate, electrolytes and vitamin B12. Indirect clinical tests for the presence of small bowel bacterial overgrowth must be supported by careful roentgenologic examination of the small intestine and intestinal aspiration studies to establish a firm pretreatment diagnosis. However, the reversal of absorptive defects by antibacterial therapy is valuable confirmatory evidence.
Article
The carbohydrate malabsorptive syndromes are frequently seen by pediatricians. The congenital deficiency states are quite rare, but adult type hypolactasia and lactose intolerance following rotavirus infection are recognized with increasing frequency by primary care physicians. Therapy for these disorders involves identification of the offending carbohydrate, removal of the carbohydrate from the diet, and exclusion of other entities that may result in carbohydrate malabsorption but not respond to its removal from the diet. Prognosis for both the primary and secondary carbohydrate malabsorption syndromes is excellent. Compliance with diets for those pediatric patients who will require lifelong therapy remains problematic.
Article
The majority of patients with celiac sprue experience diarrhea before diagnosis. There have been no studies of the prevalence or causes of chronic diarrhea in these patients after treatment with a gluten-free diet. Seventy-eight patients with celiac sprue (59 women and 19 men) treated with a gluten-free diet for at least 12 months were surveyed about their bowel habits. Those with chronic diarrhea, defined as passage of loose stools three or more times per week for 6 months, underwent an extensive diagnostic evaluation to determine its cause. Sixty-two of the 78 patients (79%) experienced diarrhea before treatment, and 13 (17%) had chronic diarrhea (of lesser severity) after treatment. The causes of diarrhea in 11 patients consenting to this study were microscopic colitis, steatorrhea secondary to exocrine pancreatic insufficiency, dietary lactose or fructose malabsorption, anal sphincter dysfunction causing fecal incontinence, and the irritable bowel syndrome. Only 1 patient had antigliadin antibodies detected in serum or small intestinal villous atrophy. After treatment of celiac sprue with a gluten-free diet, chronic diarrhea persists in a substantial percentage of patients. Although ongoing gluten ingestion is one possible cause, other causes may be more frequent. Therefore, diagnostic investigation of diarrhea in celiac sprue after treatment seems warranted.
Article
The mechanisms responsible for bowel disturbances in celiac disease are still relatively unknown. Recent reports suggested that small bowel motor abnormalities may be involved in this pathological condition; however, there are no studies addressing small bowel transit in celiac disease before and after a gluten-free diet. We studied the mouth-to-cecum transit time of a caloric liquid meal in a homogeneous group of celiac patients presenting with clinical and biochemical evidence of malabsorption and complaining of diarrhea. Sixteen patients were recruited and investigated by means of hydrogen breath test through ingestion of 20 g lactulose together with an enteral gluten-free diet formula. A urinary D-xylose test was also done in each patient. Both breath tests and D-xylose tests were carried out basally and after a period of gluten-free diet. Twenty healthy volunteers were recruited as a control group and underwent the same breath testing. At the time of the diagnosis, mouth-to-cecum transit time was significantly prolonged in celiacs with respect to controls (243 +/- 10 vs 117 +/- 6 min, P = 0.0001). The D-xylose test was also abnormal (average urinary concentration 2.8 +/- 0.25 g, normal values >4.5). No correlation was found in patients between mouth-to-cecum transit time and urinary D-xylose output (r = 0.22). After the gluten-free diet period, mouth-to-cecum transit time in celiacs was significantly reduced compared to prediet transit (134 +/- 8 vs 243 +/- 10 min, P = 0.0001) and did not show statistical difference when compared to that found in controls (P = 0.1). The D-xylose test reverted to normal in all but two subjects, who were found to be noncompliant with the diet. Mouth-to-cecum transit time is significantly prolonged in patients affected by untreated celiac disease when compared to healthy controls. This alteration might not be correlated to intestinal malabsorption, and the prolonged orocecal transit could be due to impaired small bowel function (deranged motility?). Since intestinal transit returned to normal values after an adequate gluten-free period, a link with severe active mucosal lesions is suggestive.